Last reviewed · How we verify

Zambon SpA — Portfolio Competitive Intelligence Brief

Zambon SpA pipeline: 2 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Monurol FOSFOMYCIN marketed fosfomycin Immunology 1996-01-01
Safinamide Methanesulfonate Safinamide Methanesulfonate marketed Monoamine oxidase B (MAO-B) inhibitor MAO-B (Monoamine oxidase B) Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University of Maryland, Baltimore · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zambon SpA:

Cite this brief

Drug Landscape (2026). Zambon SpA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zambon-spa. Accessed 2026-05-14.

Related